---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-045722"
form_type: "8-K"
ticker: "BOLD"
cik: "0001782303"
company_name: "Boundless Bio, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:02:17.717575+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Boundless Bio Q4 & FY 2024 net loss $65.4M; cash $152.1M; BBI-355 data expected H2 2025

## Summary
- Net loss $16.4M in Q4 2024, full year $65.4M (vs $49.4M in 2023); R&D spend rose to $55.3M.
- Cash and investments $152.1M as of Dec 31, 2024; projected operating runway into 2027.
- BBI-355 Phase 1/2 POTENTIATE trial ongoing; initial proof-of-concept safety/activity data due H2 2025.
- Novel Kinesin program: development candidate nomination targeted for mid-2025, IND submission H1 2026.
- Appointed Dr. Robert Doebele as Chief Medical Officer in February 2025.

## SEC filing metadata
- accession: 0000950170-25-045722
- form_type: 8-K
- ticker: BOLD
- cik: 0001782303
- company_name: Boundless Bio, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782303/000095017025045722/0000950170-25-045722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782303/000095017025045722/bold-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-045722
- JSON: https://secwatch.observer/filing/0000950170-25-045722.json
- Plain text: https://secwatch.observer/filing/0000950170-25-045722.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.